Study of the Efficacy and Safety of EPA in Patients With Type-2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 450 participants.
Also called NCT06129526
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 450 participants
- Sponsor
- Registry
-
NCT06129526
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Greece
- Registry status
- Unknown status
Technical summary
Registry record NCT06129526. Randomized; double masking; primary purpose prevention. Start 2023-12 (anticipated); primary completion 2024-09 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of the Efficacy and Safety of EPA in Patients With Type-2 Diabetes
- Acronym
- SEASIDE
- Condition
- Diabetes Type 2
- Condition
- Hypertriglyceridemia
- Condition
- Diabetes Mellitus
- Intervention (Dietary supplement)
- EPAVasc
- Intervention (Dietary supplement)
- Corn Oil
- Lead sponsor
- University of Ioannina
- Collaborator
- LIBYTEC Pharmaceutical S.A.
Record details
- Record id
cardio:ct-nct06129526- Content hash
b307f1135560cad4b7d92931758c26a15a29e6737d12c6874a1f4dc247156723